- Home
- AII vs MBX Comparison
AII vs MBX Comparison
Compare AII & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AII
- MBX
- Stock Information
- Founded
- AII 2006
- MBX 2018
- Country
- AII United States
- MBX United States
- Employees
- AII N/A
- MBX N/A
- Industry
- AII Property-Casualty Insurers
- MBX
- Sector
- AII Finance
- MBX
- Exchange
- AII Nasdaq
- MBX NYSE
- Market Cap
- AII 330.9M
- MBX 300.5M
- IPO Year
- AII 2025
- MBX 2024
- Fundamental
- Price
- AII $16.41
- MBX $13.64
- Analyst Decision
- AII Buy
- MBX Strong Buy
- Analyst Count
- AII 3
- MBX 5
- Target Price
- AII $21.50
- MBX $37.40
- AVG Volume (30 Days)
- AII 333.1K
- MBX 227.9K
- Earning Date
- AII 01-01-0001
- MBX 05-12-2025
- Dividend Yield
- AII N/A
- MBX N/A
- EPS Growth
- AII N/A
- MBX N/A
- EPS
- AII 1.88
- MBX N/A
- Revenue
- AII $204,354,000.00
- MBX N/A
- Revenue This Year
- AII N/A
- MBX N/A
- Revenue Next Year
- AII N/A
- MBX N/A
- P/E Ratio
- AII $0.05
- MBX N/A
- Revenue Growth
- AII 1.73
- MBX N/A
- 52 Week Low
- AII $16.02
- MBX $4.81
- 52 Week High
- AII $19.45
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- AII N/A
- MBX N/A
- Support Level
- AII N/A
- MBX N/A
- Resistance Level
- AII N/A
- MBX N/A
- Average True Range (ATR)
- AII 0.00
- MBX 0.00
- MACD
- AII 0.00
- MBX 0.00
- Stochastic Oscillator
- AII 0.00
- MBX 0.00
About AII American Integrity Insurance Group Inc. Common Stock
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.